Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) called tenofovir found its use before and after was significantly more protective against infection than a placebo gel among women at high risk of . Results of the study, known as CAPRISA 004, are to be reported at the International Conference ( 2010) in Vienna and published by the journal Science.


Read more

Related posts

Leave a Reply